J&J to Acquire Ambrx, Boosting Oncology Pipeline with Next-Gen ADCs

TL;DR

**J&J is buying Ambrx to get its cutting-edge cancer drug technology, big play for future growth.**

AI Summary

Johnson & Johnson (JNJ) announced on January 8, 2024, its definitive agreement to acquire Ambrx Biopharma, Inc. (AMAM), a clinical-stage biopharmaceutical company. This acquisition aims to bolster Johnson & Johnson's oncology portfolio, specifically by integrating Ambrx's next-generation antibody drug conjugates (ADCs), including its lead product candidate ARX517, which targets prostate-specific membrane antigen (PSMA) for cancer treatment. This move is significant for investors as it signals Johnson & Johnson's strategic investment in innovative cancer therapies, potentially driving future growth and market share in the competitive pharmaceutical industry.

Why It Matters

This acquisition strengthens Johnson & Johnson's position in the lucrative oncology market, potentially leading to new revenue streams from advanced cancer treatments. It demonstrates J&J's commitment to innovation and growth in a key therapeutic area.

Risk Assessment

Risk Level: medium — While strategic, the success of the acquisition depends on the clinical and commercial success of Ambrx's drug candidates, which is inherently risky in biopharma.

Analyst Insight

A smart investor would view this acquisition as a positive strategic move for Johnson & Johnson, reinforcing its long-term growth prospects in oncology. It might be prudent to monitor the progress of Ambrx's drug candidates under J&J's management for future valuation impacts.

Key Players & Entities

• Johnson & Johnson (company) — acquiring company
• Ambrx Biopharma, Inc. (company) — acquired company
• ARX517 (person) — lead product candidate
• January 8, 2024 (person) — date of acquisition announcement
• Brian Kenney (person) — media contact for Johnson & Johnson
• Suzanne Frost (person) — media contact for Johnson & Johnson
• Raychel Kruper (person) — investor contact for Johnson & Johnson

Forward-Looking Statements

• Johnson & Johnson's oncology pipeline will see accelerated growth and innovation due to the integration of Ambrx's ADC technology. (Johnson & Johnson) — medium confidence, target: 2025-12-31
• Ambrx's lead candidate, ARX517, will progress further in clinical trials under Johnson & Johnson's ownership. (ARX517) — medium confidence, target: 2026-12-31

FAQ

Key Financial Figures

• $2.0 b — r a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated
• $1.9 billion — value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Ambrx
• $28.00 — nding shares of Ambrxs common stock for $28.00 per share in cash through a merger of A

Filing Documents

• d653837ddefa14a.htm (DEFA14A) — 25KB
• g653837g0107023932411.jpg (GRAPHIC) — 3KB
• 0001193125-24-003957.txt ( ) — 30KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under 240.14a-12 Ambrx Biopharma, Inc. (Name of Registrant as Specified In Its Charter) Johnson & Johnson (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11. On January 8, 2024, Johnson & Johnson, a New Jersey corporation (the Company), issued the following press release in connection with the Companys entry into a definitive agreement to acquire Ambrx Biopharma, Inc. Media contacts: Brian Kenney 215-620-0111 Suzanne Frost 416-317-0304 Investor contact: Raychel Kruper investor-relations@its.jnj.com For Immediate Release Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer Portfolio of Clinical and Preclinical Programs, Including Lead Product Candidate ARX517, a Prostate-Specific Membrane Antigen (PSMA)-Targeting Antibody Drug Conjugate (ADC), Strengthens Johnson & Johnsons Commitment to Oncology Innovation Novel Technology Platform Sets Stage for the Development of Next Generation ADCs and Targeted Oncologic Therapeutics NEW BRUNSWICK, NJ (January 8, 2024) Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety of its candidate therapeutics in multiple cancer indications, including ARX517, its proprietary ADC targeting PSMA for metastatic castration-resistant prostate cancer (mCRPC); ARX788, its proprietary ADC targeting human epidermal growth factor receptor 2 (HER2) for metastatic HER2+ breast cancer; and ARX305, its proprietary ADC targeting CD-70 for renal cell carcinoma. Ambrxs ADC technology offers unique advantages in the conjugation of stable antibodies and cytotoxic linker payloads, which results in engineered ADCs that effectively kill cancer cells and limit toxicities, said Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head, Oncology, Johnson & Johnson Innovative Medicine. The results seen to date with ARX517 in mCRPC are promising and represent a potential first- and best-in-class targeted therapy for the treatment of this aggressive disease. In addition, Ambrxs pipeline and ADC platform present exciting future opportunities to deliver enhanced, precision biologics as we look to transform the treatment of cancer and improve patients lives. The planned acquisition presents a distinct opportunity for Johnson & Johnson to design, develop and commercialize targeted oncology therapeutics. Ambrxs proprietary ADC technology incorporates the advantages of highly specific targeting monoclonal antibodies securely linked to a potent chemotherapeutic payload to achieve targeted and efficient elimination of cancer cells without the prevalent side-effects typically associated with chemotherapy. Building on a legacy of innovation in oncology and in prostate cancer, J&J scientists intend to work with Ambrx researchers, accelerating the Phase 1/2 APEX-01 study ( NCT04662580 ) of ARX517 in advanced prostate cancer, while progressing a pipeline of novel ADC product candidates. With a median overall survival of less than two years and novel hormonal therapies moving earlier in the disease, significant unmet need remains in the treatment of mCRPC, said Margaret Yu, M.D., Prostate Cancer Disease Area Leader, Johnson & Johnson Innovative Medicine. We see a unique opportunity to harness the potential of this innovative ADC platform, and with our deep understanding of prostate cancer, deliver a targeted PSMA therapeutic for addressing the growing needs of the more than 185,000 patients living with metastatic castration-resistant disease today 1 . Ambrx was spun out of The Scripps Research Institute in 2003. The company pioneered the expanded genetic code technology platform for incorporation of synthetic amino acid (SAA) into proteins at any selected site using

View Full Filing

View this DEFA14A filing on SEC EDGAR